Isomorphic Labs has raised $5 billion to design new medicines with AI. In our view, that figure measures investor belief, not a drug that patients can already use.
The London company set out the $5 billion Series C, an advanced private fundraising round, in a statement dated 17 November. It called the round oversubscribed. Two investment firms, Greenoaks and Sequoia Capital, co-led it. Andreessen Horowitz and several other new backers joined, and Alphabet, the parent of Google, made what the company called a continued significant investment. Every existing investor also took part, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, a government-backed UK fund.
The same company raised $2.1 billion in a Series B round announced on 12 May. Taken together, the two cheques come to $7.1 billion in just over six months.
What the money is buying
The new funds will go into the firm’s drug design engine, called IsoDDE, and into a set of candidate medicines designed with AI. That engine is a set of simulation models used to search through chemical options and propose molecules. The company says this work is already “yielding positive preclinical results, both for internal programs in oncology and immunology and with partners, setting the stage for clinical entry.” Preclinical results are findings from tests done before a drug is given to people, usually in cells or animals.
Sir Demis Hassabis, the founder and chief executive, was clear about where the programmes stand. “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients,” he said in the same statement. Towards clinical trials means those programmes have not yet reached the point where they are tested in people.
The firm already lists research collaborations with three large drugmakers. Those partners are Novartis, Eli Lilly and Johnson & Johnson. The Novartis work, first agreed in 2024 and later expanded, is aimed at small-molecule drugs against difficult targets. The other two partnerships are also research pacts, not approved medicines.
A large cheque still buys candidates, not a pill
The $5 billion figure is real and checkable. It is also, by one specialist count, unusually large. A trade publication that tracks 26 drug companies said these two rounds were the biggest venture cheques it had recorded in the sector this year, and that the $5 billion round was the largest financing in its records since 2022.
Our reading is simpler than talk of the next generation of medicines. The company is selling a method and a list of candidates. It has not said that any of its candidates have entered human trials. Until that happens, the $5 billion is a price on belief: that simulation models can design molecules well enough to survive the much harder test of safety and benefit in people.
That is not a dismissal of the science. Preclinical results can be a genuine step. They are also the stage at which most drug candidates later fail. A fundraising round of this size does not change that filter. It only buys more attempts.
On 5 August, the founder handed over day-to-day leadership of Google DeepMind, Google’s AI lab. In a joint staff note that day, he said he would lean further into this drug company. The lab’s earlier protein-folding work is part of the scientific backdrop. We covered the next version of that system when it was released. It is not the same thing as a finished medicine.
Why it matters
A $5 billion cheque is one of the clearest numbers in the AI economy this week, and it was written for a company that will be judged by clinical trials, not by app users. That test has not started yet, and readers should keep the number and the list of candidates in separate columns.
The post Isomorphic’s $5 Billion Raise Is a Bet, Not a Medicine appeared first on DailyAI.
